市場調査レポート
商品コード
1562256

欧州の感染症治療：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通チャネル別

Europe Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
表紙：欧州の感染症治療：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通チャネル別

出版日
ページ情報
英文 106 Pages
納期
即納可能
欧州の感染症治療：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通チャネル別
出版日: 2024年07月04日
発行: The Insight Partners
ページ情報: 英文 106 Pages
納期: 即納可能
GIIご利用のメリット

  • 全表示

  • 概要
  • 図表
  • 目次
概要

欧州の感染症治療市場は、2022年に354億5,186万米ドルと評価され、2030年には491億821万米ドルに達すると予測され、2022～2030年のCAGRは4.2%と推定されます。

感染症治療の資金調達と研究開発への注目の高まりが欧州感染症治療市場を牽引

研究開発（R&D）は、バイオ医薬品や製薬企業の事業にとって極めて重要な部分です。研究開発により、医療的・商業的に大きな可能性を秘めた複数の治療用途の新製品を上市することができます。また、新興国市場の大手企業は、より高度な技術を開発し、より多くの収益シェアを獲得するために研究開発に投資しています。

欧州とその他の中東・アフリカが現在直面している最も重要な健康問題の解決策を生み出すため、欧州連合（EU）は研究、技術、革新に投資しています。欧州委員会は、特に感染症に対する免疫や感染症の管理に関連する研究を率先して推進してきました。2007～2019年の間に、43億米ドル以上が感染症の研究に割り当てられました。さらに、研究・イノベーション（R&I）のためのEUの次期（2021～2027年）資金イニシアティブであるHorizon Europeは、感染症、特に貧困に関連する感染症、顧みられない感染症、（再）新興感染症のR&I支援を継続します。

Horizon Europeは、研究とイノベーションの支援に特化したプログラムです。地域間の障壁を解消し、具体的な協力関係を構築するため、このプログラムは大学、科学コミュニティ、産業界、特に中小企業、個人間の協力を確保することに重点を置いています。保健ワークプログラムでは、感染症やパンデミックへの備えと対応に関連する研究に対するホライゾン欧州の資金提供オプション概要を示しています。このように、感染症治療の研究開発と資金調達に対する注目の高まりが、感染症治療市場の成長を後押ししています。

欧州感染症治療市場概要

欧州の感染症治療市場は、ドイツ、英国、フランス、イタリア、スペイン、その他の欧州に区分されます。欧州は世界の感染症治療市場で重要な位置を占めており、2022～2030年の間に注目すべきCAGRを記録すると推定されています。同地域では慢性ウイルス性疾患の罹患率が増加しており、新しい抗ウイルス薬の開発需要が高いです。第7次フレームワーク・プログラムとHorizon 2020を通じて2007～2019年までに157億9,000万米ドルの資金が提供され、COVID-19研究に11億米ドルの拠出が約束されていることから、欧州は感染症研究の資金提供と調整において重要な役割を果たしています。ロベルト・コッホ研究所によると、ドイツでは毎年40万人から60万人の患者が院内感染に苦しみ、そのうち1万人から1万5,000人が死亡しています。医療提供者にとっての典型的な問題は、手術部位感染、尿路感染、肺炎です。高齢者人口の増加、慢性ウイルス性疾患の有病率の増加、アンメットコンディションを満たすためのウイルス治療領域向け新分子の生産需要の高まりが原因となって、ドイツにおける抗感染症薬の需要は著しく伸びています。ドイツは抗ウイルス剤製造の主要国の一つであり、完成品の品質が高いことから、欧州での成長が期待されています。例えば、バイオ医薬品会社であるAtriva Therapeutics GmbHは、SARS-CoV-2のウイルス増殖を阻止するフェーズII試験において、COVID-19患者を治療するためにATR-002を開発しました。したがって、上記の要因により、同国の市場は大きく成長すると予想されます。

欧州感染症治療市場の収益と2030年までの予測（金額）

欧州感染症治療市場のセグメンテーション

欧州感染症治療市場は、薬剤クラス別、適応症別、投与経路別、流通チャンネル別、国別に分類されます。

薬剤クラス別では、欧州感染症治療市場は抗ウイルス薬、抗細菌薬、抗真菌薬、その他に区分されます。2022年の市場シェアは抗ウイルス剤が最大でした。

適応症では、欧州感染症治療市場はHIV、肝炎、結核、インフルエンザ、HPV、その他に区分されます。2022年にはHIVが最大の市場シェアを占めています。

投与経路に基づき、欧州感染症治療市場は経口、非経口、局所、その他に区分されます。経口剤は2022年に最大の市場シェアを占めました。

流通チャンネルでは、欧州感染症治療市場は病院薬局、小売薬局、その他に区分されます。2022年には病院薬局が最大の市場シェアを占めました。

国別では、欧州感染症治療市場はドイツ、英国、フランス、イタリア、スペイン、その他の欧州に区分されます。2022年の欧州感染症治療市場シェアはドイツが独占しています。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、BioCryst Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck &Co Inc、Pfizer Inc、Shionogi &Co Ltdは、欧州感染症治療市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州の感染症治療市場-主要市場力学

  • 欧州の感染症治療市場：主要市場力学
  • 市場促進要因
    • 感染症の有病率の上昇
    • 感染症治療の資金調達と研究開発への注目の高まり
  • 市場抑制要因
    • 抗感染症薬の耐性とそれに伴う副作用の出現
  • 市場機会
    • 抗生物質耐性の脅威の高まり
  • 今後の動向
    • 承認・上市数の増加
  • 促進要因と抑制要因の影響

第5章 感染症治療市場-欧州分析

  • 欧州の感染症治療市場売上高、2022～2030年

第6章 欧州の感染症治療市場分析-薬剤クラス別

  • イントロダクション
  • 抗ウイルス剤
  • 抗細菌薬
  • 抗真菌薬
  • その他

第7章 欧州感染症治療市場分析：適応症別

  • イントロダクション
  • HIV
  • 肝炎
  • 結核
  • インフルエンザ
  • HPV
  • その他

第8章 欧州感染症治療市場分析：投与経路別

  • イントロダクション
  • 経口
  • 非経口
  • 局所
  • その他

第9章 欧州感染症治療市場分析：流通チャンネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第10章 欧州の感染症治療市場：国別分析

  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州

第11章 感染症治療市場-業界情勢

  • イントロダクション
  • 感染症治療市場における成長戦略
    • 無機的成長戦略
  • 有機的成長戦略

第12章 企業プロファイル

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • BioCryst Pharmaceuticals Inc
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第13章 付録

図表

List Of Tables

  • Table 1. Europe Infectious Disease Therapeutics Market Segmentation
  • Table 2. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 3. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 4. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 5. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 6. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 7. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 8. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 9. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 10. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 11. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 12. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 13. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 14. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 15. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 16. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 17. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 19. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 20. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 21. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 22. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 23. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 24. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 25. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 26. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 27. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 28. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 29. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 30. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. Europe Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. Europe Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Europe Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Europe Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Europe Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Europe Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Europe Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
目次
Product Code: BMIRE00030411

The Europe infectious disease therapeutics market was valued at US$ 35,451.86 million in 2022 and is expected to reach US$ 49,108.21 million by 2030; it is estimated to register a CAGR of 4.2% from 2022 to 2030.

Increasing Focus on Funding and R&D in Infectious Disease Therapeutics Drives Europe Infectious Disease Therapeutics Market

Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.

In order to create solutions for the most important health issues that Europe and the rest of the world are currently encountering, the European Union is investing in research, technology, and innovation. The European Commission has led the way in promoting research, particularly that related to immunity to and management of infectious diseases. Between 2007 and 2019, more than US$ 4.3 billion (4 billion) was allocated to the study of infectious diseases. Further, Horizon Europe, the upcoming (2021-2027) EU funding initiative for research and innovation (R&I), will carry on supporting R&I for infectious diseases, notably those associated with poverty, those that are neglected, and those that are (re-)emerging.

Horizon Europe is a program dedicated to supporting research and innovation. To bridge barriers across regions and establish tangible collaborations, the program places a strong emphasis on ensuring cooperation between universities, scientific communities, industry, especially small and medium-sized firms, and individuals. The Health Work Programme outlines funding options under Horizon Europe for research related to infectious diseases and pandemic preparedness and response. Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.

Europe Infectious Disease Therapeutics Market Overview

The Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global infectious disease therapeutics market and is estimated to register a notable CAGR during 2022-2030. The region has an increased incidence of chronic viral diseases and a high demand for developing new anti-viral drugs. With US$ 15.79 billion funded from 2007 to 2019 through the 7th Framework Program and Horizon 2020 and the US$ 1.1 billion pledged for COVID-19 research, Europe plays a crucial role in funding and coordinating research on infectious diseases. According to The Robert Koch Institute, in Germany, ~400,000 to 600,000 patients suffer a hospital-acquired infection each year, among which 10,000-15,000 die. Typical problems for healthcare providers are surgical site infections, urinary tract infections, and pneumonia. The demand for anti-infective agents in Germany is growing significantly, attributed to the rising geriatric population, the increasing prevalence of chronic viral diseases, and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions. Germany is one of the leading nations for anti-viral agent manufacturing and growth potential in Europe due to the high quality of its finished products. For instance, Atriva Therapeutics GmbH, a biopharmaceutical company, developed ATR-002 to treat patients with COVID-19 in a Phase II Study to block viral propagation of SARS-CoV-2. Therefore, due to the abovementioned factors, the market is expected to grow significantly in the country.

Europe Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Infectious Disease Therapeutics Market Segmentation

The Europe infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Europe infectious disease therapeutics market is segmented into anti-viral, anti bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Europe infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Europe infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Europe infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Europe infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Europe Analysis

  • 5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 Europe Infectious Disease Therapeutics Market
    • 10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.8.1 Overview
      • 10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.10.1 Overview
      • 10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.12.1 Overview
      • 10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 BioCryst Pharmaceuticals Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 GSK Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AbbVie Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Merck & Co Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Astellas Pharma Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners